Ziccum receives research grant from Vinnova AB (publ)

28 June, 2019

The evaluation will take place in the ‘TESTA Center’ laboratories in Uppsala in premises that comply with BSL2 (Biosafety Level 2) standards, the required standard for collaboration with industrial partners on vaccine development.


For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99


About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on June 28, 2019.